SLU-PP-332 vs HGH Fragment 176-191
Side-by-side comparison of key properties, dosing, and research.
Recovery & RepairFat Loss & Metabolic
SLU-PP-332Fat Loss & Metabolic
HGH Fragment 176-191- Summary
- SLU-PP-332 is a small molecule exercise mimetic that activates estrogen-related receptors ERRalpha and ERRdelta (ERRa/d), transcription factors that drive oxidative metabolism programs. In animal studies it significantly enhanced endurance capacity and metabolic fitness without exercise, mimicking many of the cardiovascular and metabolic adaptations of aerobic training.
- HGH Fragment 176-191 (also known as AOD-9604) is a stabilized, modified fragment of the human growth hormone molecule corresponding to amino acids 176–191 with an addition of a tyrosine residue at the N-terminus. It retains HGH's fat-burning properties without the anabolic, diabetogenic, or IGF-1-stimulating effects.
- Half-Life
- Not established in humans; rodent pharmacokinetics suggest hours
- ~30 minutes
- Admin Route
- Oral (research), Subcutaneous (research)
- SubQ
- Research
- —
- —
- Typical Dose
- Not established for humans; rodent studies used ~100 mg/kg/day
- 250–500 mcg
- Frequency
- Once daily in rodent studies
- 1–3 times daily
- Key Benefits
- Significant enhancement of aerobic endurance capacity
- Increases mitochondrial density and oxidative metabolism in muscle
- Promotes beneficial shift toward oxidative muscle fiber phenotype
- Improves cardiac efficiency and cardiovascular fitness markers
- Potential for obesity, metabolic syndrome, and heart failure treatment
- Exercise mimetic for populations unable to exercise (disability, frailty, disease)
- Selective fat burning without anabolic side effects
- Reduces visceral and subcutaneous fat
- No insulin resistance or blood glucose disruption
- Does not stimulate IGF-1
- May support cartilage and bone repair (at higher doses)
- No effect on growth or organ size
- Side Effects
- Limited human data; all studies are preclinical (rodent)
- Unknown cardiovascular effects with long-term or high-dose use in humans
- Potential hormonal interactions via ERR pathway (ERRs modulate estrogen-related signaling)
- Off-target effects not fully characterized
- Injection site irritation
- Temporary lethargy
- Headache (rare)
- Nausea (rare)
- Stacks With
- —
- —